Skip to main content
SpringerLink
Log in
Book cover

Endocrinology of Breast Cancer pp 347–357Cite as

Hormonal Treatment of Fibrocystic Disease

  • Chapter

  • 119 Accesses

Part of the book series: Contemporary Endocrinology ((COE,volume 11))

Abstract

The term benign breast disease (BBD) has been employed to indicate a wide and heterogeneous group of different morphologic and clinical entities. Many authors have used the term fibrocystic breast disease (FCD) to indicate a clinical picture including diffuse nodularity, with or without pain, mainly occurring in the reproductive age; the term is unsatisfactory, but we will refer to FCD because a considerable body of literature stands on this terminology (1,2).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angeli A, Dogliotti L, Faggiuolo R, Orlandi F, Bussolati G, eds. (1984) Fibrocystic Disease of the Breast. A Revisit and New Perspectives, Excerpta Medica, Amsterdam.

    Google Scholar 

  2. Dogliotti L, Orlandi F, Angeli A (1989) The endocrine basis of benign breast disorders. World J Surg 13: 674–679.

    Article  PubMed  CAS  Google Scholar 

  3. Haagensen CD, Bodian C, Haagensen DE Jr (1981) Breast Carcinoma. Risk and Detection. WB Saunders, Philadelphia.

    Google Scholar 

  4. Azzopardi JC (1979) Problems in Breast Pathology. WB Saunders, Philadelphia.

    Google Scholar 

  5. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. (1993) Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71: 1258–1263.

    Article  PubMed  CAS  Google Scholar 

  6. Schuerch C, Rosen PP, Hirota T, Itabashi M, Yamamoto H, Kinnie DW, et al. (1982) A pathologic study of benign breast disease in Tokyo and New York. Cancer 50: 1899–1903.

    Article  PubMed  Google Scholar 

  7. Bruzzi P, Dogliotti L, Naldoni C, Bucchi L, Costantini M, Cicognani A, et al. (1997) Cohort study of association of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ 314: 925–928.

    Article  PubMed  CAS  Google Scholar 

  8. Love SM, Gelman RS, Site W (1982) Fibrocystic `disease’ of the breast-a non disease? N Engl J Med 307: 1010–1014.

    Article  PubMed  CAS  Google Scholar 

  9. Osborne MP (1987) Breast development and anatomy, In: Breast Disease ( Harris JR, Hallman S, Henderson IC, Kinne DW, eds.), JB Lippincott, Philadelphia, pp. 1–14.

    Google Scholar 

  10. Russo J, Russo IH (1987) Development of the human mammary gland, In: The Mammary Gland ( Neville MC, Daniel CW, eds.), Plenum, New York, pp. 67–93.

    Google Scholar 

  11. Love SM, Schmitt SJ, Connolly JL, Shirley RL (1987) Benign breast disorders, In: Breast Disease ( Harris JR, Hellman S, Craig L, Kinne DW, eds.), JB Lippincott, Philadelphia, pp. 15–73.

    Google Scholar 

  12. Hughes E, Bundred NJ (1989) Breast macrocysts. World J Surg 13: 711–714.

    Article  PubMed  CAS  Google Scholar 

  13. Hinton CP, Williams MR, Roebuck CJ, Blamey R (1986) A controlled trial of danazol in the treatment of multiple recurrent breast cysts. Br J Clin Pract 40: 3–5.

    Google Scholar 

  14. Locker AP, Hinton CP, Roebuck EJ, Blarney RW (1989) Long term follow-up of patients treated with a single course of danazol for recurrent breast cysts. Br J Clin Pract 43 (suppl 68): 100–101.

    Google Scholar 

  15. Rasmussen T, Tobiassen T, Doberl A (1986) Reduction of cysts in fibrocystic breast disease during and after danazol treatment. Ann NY Acad Sci 464: 622–625.

    Article  Google Scholar 

  16. Leis HP Jr (1989) Management of nipple discharge. Br J Surg 13: 736–742.

    Google Scholar 

  17. Peters F, Schuth W (1989) Hyperprolactinemia and nonpuerperal mastitis (duct ectasia). JAMA 261, 1618–1620.

    Article  PubMed  CAS  Google Scholar 

  18. Haagensen CD (1986) The normal physiology of the breast, In: Disease of the Breast, 3rd ed. ( Haagensen CD, ed.), WB Saunders, Philadelphia, pp 47–55.

    Google Scholar 

  19. Preece PE, Mansel RE, Hughes LE (1978) Mastalgia: psychoneurosis or organic disease? BMJ 1: 29–34.

    Article  PubMed  CAS  Google Scholar 

  20. Maddox ER, Mansel RE (1989) Management of breast pain and nodularity. World J Surg 13: 669–705.

    Article  Google Scholar 

  21. Mansel RE (1993) Guidelines for referral by general practitioners, In: Recent Developments in the Study of Benign Breast Disease ( Mansel RE, ed.), Parthenon, London, pp. 25–32.

    Google Scholar 

  22. Pye JK, Mansel RE, Hughes LE (1985) Clinical experience of drug treatment for mastalgia. Lancet 2: 373–377.

    Article  PubMed  CAS  Google Scholar 

  23. Sibbering M, Galea MH, Blarney RW (1993) Chest wall pain in the mastalgia clinic, In: Recent Progress in the Study of Benign Breast Disease ( Mansel RE, ed.), Parthenon, London, pp. 201–206.

    Google Scholar 

  24. Maddox PR, Harrison BJ, Mansel RE, Hughes LE (1989) Non-cyclical mastalgia: an improved classification and treatment. Br J Surg 76: 901–907.

    Article  PubMed  CAS  Google Scholar 

  25. Gateley CA, Maddox PR, Pritchard GA, Shendan W, Harrison BJ, Pye GK, et al. (1992) Plasma fatty acid profiles in benign breast disorders. Br J Surg 79: 407–410.

    Article  PubMed  CAS  Google Scholar 

  26. Sherins RJ, Gandy HM, Thorslund TW, Paulsen CA (1971) Pituitary and testicular function studies. I. Experience with a new gonadal inhibitor, danazol. J Clin Endocrinol Metab 32: 522–531.

    Google Scholar 

  27. Dmowski WP (1979) Endocrine properties and clinical application of danazol. Fertil Steril 31: 237–242.

    PubMed  CAS  Google Scholar 

  28. Franchimont P, Cramillon C (1977) The effect of danazol on anterior pituitary function. Fertil Steril 28: 814–817.

    PubMed  CAS  Google Scholar 

  29. Lind T, Cook DB (1976): How does danazol work? Lancet 1: 1401–1402.

    Article  PubMed  CAS  Google Scholar 

  30. Barbieri RL, Ryan KJ (1981) Danazol: endocrine pharmacology and therapeutic applications. Am J Obstet Gynecol 141: 453–463.

    PubMed  CAS  Google Scholar 

  31. Bevan JR, Dowsett M, Jeffcoate SL (1984) Endocrine effects of danazol in the treatment of endometriosis. Br J Obstet Gynecol 91: 160–166.

    Article  CAS  Google Scholar 

  32. Rannevik G (1987) Hormonal effects of danazol, In: Benign breast disease: Is it worth treating (Wood C, ed.), The Royal Society of Medicine Service, Roundtable Series no. 6, London, pp. 93–99.

    Google Scholar 

  33. Greenblatt RB, Chadda JS, Teran AZ, Lewis A (1984) Fibrocystic breast disease: pathophysiology, hormonology, treatment. Contemp Surg 24: 49–60.

    Google Scholar 

  34. Menon M, Azhar S, Menon KMJ. (1980) Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotrophin-receptor interaction and cyclical AMP formation. Am J Obstet Gynaecol 136: 524–530.

    CAS  Google Scholar 

  35. Panahy C, Pucklefoot JR,Anderson E, Winson GP, Berry CL, Goode AW (1987) Effect of danazol on the incidence of progesterone and estrogen receptors in benign breast disease. BMJ 295: 464–466.

    Article  PubMed  CAS  Google Scholar 

  36. Bonhet HG, Hanker JP, Schweppe KW, Schneider HPG (1981) Changes ofprolactin secretion following long term danazol application. Fertil Steril 36: 725–728.

    Google Scholar 

  37. Greenblatt RB, Dmowsky WP, Mahesh VB, Scholler HFL (1971) Clinical studies with anantigonadotropin, danazol Fertil Steril 22: 102–112.

    CAS  Google Scholar 

  38. Lauersen NH, Wilson KH (1976) The effect of danazol in the treatment of chronic cystic mastitis. Obstet Gynecol 48: 93–98.

    PubMed  CAS  Google Scholar 

  39. Asch RH, Greenblatt RB (1977) The use of an impeded androgen-danazol-in the management of benign breast disorders. Am J Obstet Gynaecol 127: 130–134.

    CAS  Google Scholar 

  40. Brookshaw JD (1980) Danazol treatment of benign breast disease: a survey of USA multicenter study. Postgrad Med J 55 (suppl 5): 52–58.

    Google Scholar 

  41. Greenblatt RB, Nezhat C, Ben Nun I (1980) The treatment of benign breast disease with danazol. Fertil Steril 34: 242–245.

    PubMed  CAS  Google Scholar 

  42. Mansel RE, Wisbey JR, Hughes LE (1982) Controlled trial of the anti-gonadotropin danazol in painful nodular benign breast disease. Lancet 1: 928–930.

    Article  PubMed  CAS  Google Scholar 

  43. Hinton CP, Bishop HN, Holliday HW, Doyle PJ, Blamey RW (1986) A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical brest pain. Br J Clin Pract 40: 326–330.

    PubMed  CAS  Google Scholar 

  44. Wentz AC (1982) Adverse effects of danazol in pregnancy. Ann Intern Med 96: 672–675.

    PubMed  CAS  Google Scholar 

  45. Maddox PR, Harrison J, Mansel RE (1989) Low dose danazol for mastalgia. Br J Clin Pract 43 (suppl 68): 43–47.

    Google Scholar 

  46. Thorner MO, Fluckiger E, Kalne DB (1980) Bromocriptine: A Clinical and Pharmacological Review. Raven Press, New York.

    Google Scholar 

  47. Schulz KD, Del Pozo E, Lose KH (1975) Successful treatment of mastodynia with the prolactin inhibitor bromocriptine (CB-154). Arch Gynaekol 220: 83–87.

    Article  CAS  Google Scholar 

  48. Benedek-Jaszman LJ, Hearn-Sturtevant MD (1976) Premenstrual tension and functional infertility. Aetiology and treatment. Lancet 2: 1095–1098.

    Google Scholar 

  49. Dalton K (1976) Bromocriptine in premenstrual syndrome, In: Pharmacological and Clinical Aspects of Bromocriptine (Parlodel) ( Bayliss RIS, Turner P, McLay WP, eds.), Grange Press, Southwick, pp. 106–110.

    Google Scholar 

  50. Andersch B, Hahn L, Wendestruan C (1978) Treatment of premenstrual tension syndrome with bromocriptine. Acta Endocrinol 88 (suppl 216): 165.

    Google Scholar 

  51. Harrisson P, Letchworth AJ (1976) Bromocriptine in the treatment of premenstural tension syndrome, In: Pharmacological and Clinical Aspects of Bromocriptine (Parlodel) ( Bayliss RIS, Turner P, McLay WP, ed.), Grange Press, Southwick, pp. 103–105.

    Google Scholar 

  52. Andersen AN, Larsen JF, Steenstrup OR (1977) Effect of bromocriptine on the premenstrual syndrome. A double-blind clinical trial. Br J Obstet Gynecol 84: 370–374.

    Google Scholar 

  53. Graham JJ, Harding PE, Wise PH, Berriman H (1978) Prolactin suppression in the treatment of premenstrual syndrome. Med J Aust Supplement: 18 20.

    Google Scholar 

  54. Elsner CW, Buster JE, Shindel RA (1980) Bromocriptine in the treatment of premenstrual tension syndrome. Obstet Gynaecol 56: 723–727.

    CAS  Google Scholar 

  55. Ylostalo P, Kauppila A, Puolakka J, et al. (1982) Bromocriptine and norethisterone in the treatment of premenstrual syndrome. Obstet Gynecol 59: 292–298.

    PubMed  CAS  Google Scholar 

  56. Mansel RE, Preece PE, Hughes LE (1978) A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg 65: 724–727.

    Article  PubMed  CAS  Google Scholar 

  57. Durning P, Sellwood RA (1982) Bromocriptine in severe cyclical breast pain. Br J Surg 69: 248–249.

    Article  PubMed  CAS  Google Scholar 

  58. Blicher-Toft M, Anderson AN, Henriksen OB, Mygind T (1979) Treatment of mastalgia with bromocriptine: a double blind crossover study. BMJ 1: 237.

    Article  Google Scholar 

  59. Mansel RE, Dogliotti L (1990) European multicentre trial of bromocriptine in cyclical mastalgia. Lancet 335: 190–193.

    Article  PubMed  CAS  Google Scholar 

  60. Kumar S, Mansel RE, Hughes LE, Edwards CA, Scanlon MF (1985) Prediction of response to endocrine therapy in pronounced cyclical mastalgia using dynamic tests of prolactin release. Clin Endocrinol 23: 669–672.

    Article  Google Scholar 

  61. Sitruk-Ware R, Sterkers N, Mowszowicz I, Mauvais-Jarvis P (1977) Inadequate corpus luteus function in women with benign breast diseases. J Clin Endocrinol Metab 44: 771–774.

    Article  PubMed  CAS  Google Scholar 

  62. Mauvais-Jarvis P, Sterkers N, Kuttenn F, Beauvais J (1978) Traitement des mastopathies benignes par la progesterone, et les progestatifs. J Gynaecol Obstet Biol Reprod 7: 477–484.

    CAS  Google Scholar 

  63. Kuttenn F, Fournier S, Sitruk-Ware R, et al. (1983) Progesterone insufficiency in benign breast disease, In: Endocrinology of Cystic Breast Disease ( Angeli A, Bradlow HL, Dogliotti L, eds.), Raven Press, New York, pp. 231–233.

    Google Scholar 

  64. Vorherr H (1986) Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture and management. Am J Obstet Gynaecol 154: 161–167.

    CAS  Google Scholar 

  65. Kuttenn F, Mouttarege A, Mauvais-Jarvis P (1978) Bases hormonales de la contraception progestative discontinué. Nouv Press Med 7: 3109–3113.

    CAS  Google Scholar 

  66. Dennerstein L, Spencer-Gardiner C, Gotts G (1985) Progesterone and premenstrual syndrome: a double blind crossover trial. BMJ 290: 1617–1621.

    Article  PubMed  CAS  Google Scholar 

  67. Colin C, Gaspard U, Lambotte R (1978) Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol. Arch Gynaekol 225: 7–13.

    Article  CAS  Google Scholar 

  68. Day JB (1979) Clinical trials in premenstrual syndrome. Curr Med Res Opin 6 (suppl 5): 40–45.

    Article  Google Scholar 

  69. Ory H, Cole P, MacMahon B (1976) Oral contraceptives and reduced risk of benign breast disease. N Engl J Med 294: 419.

    Article  PubMed  CAS  Google Scholar 

  70. Ricciardi I, Ianniruberto A (1979) Tamoxifen induced regression of benign breast lesion. Obstet Gynecol 54: 80–84.

    Article  PubMed  CAS  Google Scholar 

  71. Fentiman IS, Caleffi M, Brame K, Chaudary MA, Hayward JL (1986) Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet 1: 287–288.

    Article  PubMed  CAS  Google Scholar 

  72. Fentiman IS, Caleffi M, Hamed H, Chaudary MA (1988) Dosage and duration of tamoxifen treatment for mastalgia: a randomized trial. Br J Surg 75: 845–846.

    Article  PubMed  CAS  Google Scholar 

  73. Sherman BM, Chapler FK, Crikard K (1979) Endocrine consequences ofcontinuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 64: 398–404.

    Article  PubMed  CAS  Google Scholar 

  74. Fentiman IS, Powles Ti (1987) Tamoxifen and benign breast conditions. Lancet 2: 1070–1071.

    Article  PubMed  CAS  Google Scholar 

  75. Hamed H, Caleffi M, Chaudary MA, Fentiman IS (1990) LHRH analogue for treatment of recurrent and refractory mastalgia: a controlled trial. Br J Surg 75: 845–848.

    Google Scholar 

Download references

Authors
  1. Luigi Dogliotti MD,PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pasquale Caraci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. College of Medicine, The Pennsylvania State University, Hershey, PA, USA

    Andrea Manni MD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dogliotti, L., Caraci, P. (1999). Hormonal Treatment of Fibrocystic Disease. In: Manni, A. (eds) Endocrinology of Breast Cancer. Contemporary Endocrinology, vol 11. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-699-7_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-699-7_22

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5139-0

  • Online ISBN: 978-1-59259-699-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation